p-methoxyphenacyl bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: p-methoxyphenacyl bromide
• 英文别名: 4-Methoxyphenacetyl bromide；2-(4-methoxyphenyl)acetyl bromide
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: RTXJHRATXJCDMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  p-methoxyphenacyl bromide 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 文拉法辛杂质4
  参考文献：
  名称：

  Hammett Analysis of Photodecarbonylation in Crystalline 1,3-Diarylacetones

  摘要：

  The relative quantum yields and chemical efficiencies of crystalline p,p'-disubstituted 1,3-diphenyl-2-propanones with 4-MeO2 4Me(2) 4-F-2 4-CF3, and 3,4-diMeO groups were determined by parallel irradiation of polycrystalline samples. Variations in quantum yields that span a factor of 4 are analyzed in terms of the effects of substituents on the stability of the benzylic radical. All solid-state reactions proceeded with 100% chemoselectivity and in >95% chemical yield.

  DOI：

  10.1021/ol0480527

文献信息

• [EN] 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL- OU 2-HÉTARYL-IMIDAZOL[1,2-A]PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014177458A1

  公开（公告）日：2014-11-06

  The invention relates to compounds of formulas I and II, formula I or formula II wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, S-lower alkyl, lower alkoxy substituted by halogen, di-lower alkyl amino, C(O)O-lower alkyl, lower alkyl substituted by hydroxy or hydroxy; R2 is hydrogen, lower alkyl, halogen, lower alkoxy, S-lower alkyl, lower alkoxy substituted by halogen, O(CH2)2-lower alkoxy substituted by halogen, di-lower alkyl amino, alkyl amino, NH-lower alkyl substituted by halogen, N(lower alkyl)-benzyl, lower alkyl substituted by hydroxy, heterocycloalkyl optionally substituted by halogen, CH2-lower alkoxy, CH2-lower alkoxy substituted by halogen or hydroxy; or R1 and R2 form together with the carbon atoms to which they are attached a ring containing -OCH2CH2O-, OCH2O-, OCH2CH2CH2O- or -NHC(O)CH2O-; R3 is hydrogen or lower alkoxy; R4 is hydrogen or lower alkyl; R5 is lower alkyl, cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or R4 and R5 form together with the nitrogen atom to which they are attached a ring containing -CH2CH2CHRCH2CH2-, -CH2CHRCH2CH2-, -CH2CH2OCH2CH2-, -CH2CH2NR'CH2CH2-, CH2CHR- or -CH2CH2CH2-; wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R' is lower alkyl substituted by halogen; Ra is hydrogen or H; Rb is hydrogen, hydroxy or 3H; R6 is hydrogen, halogen or lower alkyl; HetAr is selected from the group consisting of thiophenyl, furanyl, thiozolyl, benzofuranyl, pyrazolyl, benzoimidazolyl or pyridinyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The present compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.

  本发明涉及式I和式II的化合物，式I或式II中，R1为氢、低级烷基、低级烷氧基、卤素、S-低级烷基、卤素取代的低级烷氧基、二-低级烷基氨基、C(O)O-低级烷基、羟基取代的低级烷基或羟基；R2为氢、低级烷基、卤素、低级烷氧基、S-低级烷基、卤素取代的低级烷氧基、O(CH2)2-卤素取代的低级烷氧基、二-低级烷基氨基、烷基氨基、NH-卤素取代的低级烷基、N(低级烷基)-苄基、羟基取代的低级烷基、任选卤素取代的杂环烷基、CH2-低级烷氧基、CH2-卤素或羟基取代的低级烷氧基；或者R1和R2与其所连接的碳原子一起形成含有-OCH2CH2O-、OCH2O-、OCH2CH2CH2O-或-NHC(O)CH2O-的环；R3为氢或低级烷氧基；R4为氢或低级烷基；R5为低级烷基、环烷基、羟基取代的低级烷基或卤素取代的低级烷基；或者R4和R5与其所连接的氮原子一起形成含有-CH2CH2CHRCH2CH2-、-CH2CHRCH2CH2-、-CH2CH2OCH2CH2-、-CH2CH2NR'CH2CH2-、CH2CHR-或-CH2CH2CH2-的环；其中R为氢、卤素、低级烷基、低级烷氧基或卤素取代的低级烷基；R'为卤素取代的低级烷基；Ra为氢或H；Rb为氢、羟基或3H；R6为氢、卤素或低级烷基；HetAr选自噻吩基、呋喃基、噻唑基、苯并呋喃基、吡唑基、苯并咪唑基或吡啶基；n为1或2；或为药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。本发明的化合物适合作为成像工具，通过识别大脑中tau聚集体过量的潜在患者，将有助于改善诊断，这些患者可能发展为阿尔茨海默病。
• [EN] IMIDAZO[1,2-A]PYRIDIN-7-AMINES AS IMAGING TOOLS<br/>[FR] IMIDAZO[1,2-A]PYRIDIN-7-AMINES EN TANT QU'OUTILS D'IMAGERIE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015044095A1

  公开（公告）日：2015-04-02

  The present invention relates to compounds of general formula (I) wherein R1 is lower alkyl or lower alkyl substituted by halogen; R2, R3 are hydrogen or tritium; or to a pharmaceutically acceptable acid addition salt. The compounds may be used for binding and imaging tau aggregates and related beta-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates.

  本发明涉及一般式（I）中R1为较低烷基或被卤素取代的较低烷基；R2、R3为氢或氚；或药用可接受的酸盐。这些化合物可用于结合和成像tau聚集物和相关的β-折叠蛋白聚集物，包括除其他外的β-淀粉样聚集物或α-突触核蛋白聚集物。
• Synthesis of N3-Substituted Uridine and Related Pyrimidine Nucleosides and Their Antinociceptive Effects in Mice
  作者：Tomomi Shimizu、Toshiyuki Kimura、Tatsuya Funahashi、Kazuhito Watanabe、Ing Kang Ho、Ikuo Yamamoto

  DOI：10.1248/cpb.53.313

  日期：——

  antinociceptive effects of three derivatives were 5.8, 5.4, and 5.1-folds of the effect of N(3)-phenacyluridine (1h) (16%), respectively. The structure-activity relationship of N(3)-substituted pyrimidine nucleosides was also discussed.

  尿苷（1），胸苷（2），2'-脱氧尿苷（3），6-氮杂尿苷（4），2'，3'-O-异丙基亚尿苷（5）和阿拉伯呋喃呋喃糖基尿嘧啶的七十八个N（3）取代衍生物（6）被合成并评估其抗伤害作用。N（3）-（2'，4'-二甲氧基苯甲酰基）尿苷（1l），N（3）-（2'，4'-二甲氧基苯甲酰基）2'-脱氧尿苷（3l）和N（3）-（2'通过热板测试，5'-二甲氧基苯甲酰基）呋喃糖基尿嘧啶阿拉伯糖（6m）分别具有93％，86％和82％的抗伤害感受作用。三种衍生物的抗伤害感受作用分别是N（3）-苯并吡啶（1h）（16％）的作用的5.8、5.4和5.1倍。N（3）取代的嘧啶核苷的结构活性关系也进行了讨论。
• Novel [1,2,4]triazolo[3,4‐ <i>b</i> ][1,3,4]thiadiazine derivatives embedded with benzimidazole moiety as potent antioxidants
  作者：Reshma Sathyanarayana、Boja Poojary、Revanasiddappa B. Chandrashekarappa、Hemanth Kumar、Vijay K. Merugumolu

  DOI：10.1002/jccs.201900452

  日期：2020.8

  and nitric oxide radical with IC50 values of 13.57 and 18.55 μg/ml when compared to the standard with IC50 values of 23.75 and 23.14 μg/ml, respectively, which was due to the presence of electron‐donating groups. The activity was found to decline when electron‐donating groups were replaced by electron‐withdrawing groups. Moderate scavenging activity was observed for the superoxide radical. Structure

  使用一锅硝基还原环化方法合成了十四种带有苯并咪唑部分（7a-n）的新型[1,2,4]三唑[3,4– b ] [1,3,4]噻二嗪衍生物。所有合成的化合物均通过1 H核磁共振（1 H NMR），13 C NMR，傅立叶变换红外（FT-IR），质谱和元素分析得到确认。所有标题化合物均经受体外抗氧化活性。使用DPPH，一氧化氮和超氧化物自由基清除方法检查化合物的自由基清除活性。结果表明，化合物3-（2-（3,4-二甲氧基苯基）-1-丙基-1 H-苯并[ d]咪达唑-5-基）-6-4-甲苯基7 H- [1,2,4]三唑[3,4- b ] [1,3,4]噻二嗪（7c）对清除DPPH和一氧化氮自由基的IC 50值为13.57和18.55μg/ ml，而标准品的IC 50值为23.75和23.14μg/ ml，这是由于存在供电子基团。当给电子基团被吸电子基团取代时，活性下降。观察到超氧化物自由基的中等清
• A Mild and Efficient Synthesis of Novel Isoxazolyl-Benzo[<i>d</i>]Pyrazino[2,1-<i>b</i>] [1,3]Oxazoles
  作者：Eligeti Rajanarendar、Paka Venkateshwarlu、Saini Ramakrishna、Dharavath Nagaraju

  DOI：10.1002/jhet.2064

  日期：2015.7

  Synthesis of novel 2‐3‐methyl‐5‐[(E)‐2‐aryl‐1‐ethenyl]‐4‐isoxazolyl‐4,10a‐diaryl‐1,10a‐dihydro‐2H‐benzo[d]pyrazino[2,1‐b][1,3]oxazoles 5 were simply achieved by the reaction of 2‐[3‐methyl‐5‐[(E)‐2‐aryl‐1‐ethenyl]‐4‐isoxazolyl(2‐oxo‐2‐arylethyl)amino]‐1‐aryl‐1‐ethanones 3 with o‐aminophenol 4 in the presence of CAN catalyst. The intermediates, 2‐[3‐methyl‐5‐[(E)‐2‐aryl‐1‐ethenyl]‐4‐isoxazolyl(2‐ox

  新型2-3-甲基-5-[（E）-2-芳基-1-乙烯基] -4-异恶唑基-4,10a-二芳基-1,10a-二氢-2 H-苯并[ d ]吡嗪并[ 2,1- b ] [1,3]恶唑5可以通过2- [3-甲基-5-[（E）-2-芳基-1-乙烯基] -4-异恶唑基（2-oxo）的反应简单地获得-2-芳基乙基）氨基] -1-芳基-1-乙基酮3与邻氨基苯酚4在CAN催化剂的存在下。中间体2- [3-甲基-5 [[ E）-2-芳基-1-乙烯基] -4-异恶唑基（2-氧代-2-芳基乙基）氨基] -1-芳基-1-乙酮3，由4-氨基-3-甲基-5-苯乙烯基恶唑1反应制得，在K 2 CO 3存在下与苯乙酰胺2在乙醇中的溶液。新合成的化合物3a，3b，3c，3d，3e，3f，3g，3h，3i，3j，3k，3l和5a，5b，5c，5d，5e，5f，5g，5h，5i，5j的结构，5k，5l已通过分析和光谱数据确认。